Key Points
- Insider selling: Johanna Mercier sold 3,000 Gilead shares on Mar 16 at an average $144.23 (~$432,690), trimming her position by 2.23%; CFO Andrew D. Dickinson also sold 3,000 shares the same day and Mercier had previously sold 28,000 shares on Feb 17.
- Strong quarterly results and guidance: Gilead beat EPS ($1.86 vs. $1.83) and revenue ($7.93B vs. $7.68B), with revenue up 4.7% year‑over‑year and FY2026 EPS guidance of $8.45–$8.85.
- Dividend increase: The company raised its quarterly dividend to $0.82 ($3.28 annualized) for a 2.3% yield, with an ex‑dividend date of Mar 13 and payment on Mar 30.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the insider directly owned 131,779 shares of the company's stock, valued at $19,006,485.17. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Johanna Mercier also recently made the following trade(s):
- On Tuesday, February 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00.
- On Thursday, January 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00.
Gilead Sciences Stock Performance
Shares of GILD opened at $144.40 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market cap of $179.26 billion, a P/E ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.37. The company has a 50-day moving average of $141.62 and a two-hundred day moving average of $127.41. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the business earned $1.90 earnings per share. The company's quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is currently 48.45%.
Hedge Funds Weigh In On Gilead Sciences
Institutional investors have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth about $26,000. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $26,000. Finally, Wealth Preservation Advisors LLC increased its position in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 81 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Arcellx / takeover-related coverage — reports note a Gilead-related takeover theme that drove a big one‑day move in a small biotech (Arcellx). M&A activity or strategic deals in cell therapy could be viewed positively for Gilead’s pipeline expansion and long-term growth prospects. This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
- Neutral Sentiment: Unusual options activity flagged by market scanners — Barchart/MSN highlighted Gilead among mega‑caps with unusual options flows, which can signal speculative interest or hedging by institutions but is ambiguous for directional bias. Monitor option volumes and put/call skew for confirmation. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
- Negative Sentiment: Insider sale — Johanna Mercier sold 3,000 shares at an average $144.23 on Mar 16 (disclosed to the SEC). Insider selling can be interpreted negatively by investors even if part of routine diversification or pre-set plans. Insider Sale - Johanna Mercier (SEC Filing)
- Negative Sentiment: Insider sale — CFO Andrew D. Dickinson also sold 3,000 shares at an average $144.23 on Mar 16. A sale by the CFO can draw extra attention from investors and may weigh on sentiment in the near term. Insider Sale - Andrew D. Dickinson (SEC Filing)
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a "buy" rating and a $180.00 price objective for the company. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the company a "buy" rating in a research note on Wednesday, February 11th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a "sector perform" rating in a report on Wednesday, February 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $170.00 price target on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $157.62.
View Our Latest Research Report on GILD
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
